The company and the board of directors ensure that the information disclosed is true, accurate, and complete, without any false records, misleading statements, or major omissions.
Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company" or "this Company") held the 2026 Annual General Meeting on April 21, 2026, to discuss the provision for asset impairment for 2025, and the specific situation is as follows:
Overview of Asset Impairment Provision
Reasons for Asset Impairment Provision
To be truthful, the accurate reflection of the company's financial status and asset value, based on the "Enterprise Accounting Standards" and the company's policy regulations, the company will report the asset impairment provision as of December 31, 2025, and will conduct a comprehensive assessment of whether each asset requires impairment analysis based on the principle of prudence.
Scope of Provision Calculation, Total Amount, and Reporting Period
The company’s provision for asset impairment covers revenue from various sources, other income, and fixed assets. This report indicates that the total amount for the asset impairment provision is 7,742.85 million yuan. The specific situation is as follows:
| Asset Impairment Name | 2025 Calculation/Year | Provision Amount (10,000 yuan) | Remarks |
|---|---|---|---|
| Credit Impairment | -623.74 | ||
| Total Credit Impairment | -982.38 | ||
| Other Income | 358.64 | ||
| Total Impairment | 8,366.59 | Total | |
| 1,506.29 |